Abstract
Cold agglutinin disease (CAD) is a rare type of autoimmune hemolytic anemia (AIHA) distinct from warm antibody AIHA. One of the ways it is distinct is that CAD is usually not responsive to corticosteroids compared with warm antibody AIHA. Historically, CAD therapy has been limited to immunotherapy or chemoimmunotherapy with varying responses. Cold agglutinin disease also poses a risk for thrombosis and mortality. For patients, fatigue tends to be a common symptom of CAD. The hallmark of CAD is complement-mediated hemolysis, which makes complement inhibitors a critical therapeutic option for patients. Previously, eculizumab, a C5 inhibitor, had limited therapeutic effect for CAD. More recently, sutimlimab, a C1s inhibitor, was shown in two phase III studies to be an efficacious treatment for CAD, improving hemoglobin, hemolysis, and fatigue. However, there is a paucity of medical literature on CAD and on sutimlimab in particular that is geared toward advanced practice providers (APPs). This article aims to provide APPs with a background in CAD and a focus on sutimlimab, assisting these providers in caring for patients with CAD receiving this therapy.
References
Acaster, S., Dickerhoof, R., DeBusk, K., Bernard, K., Strauss, W., & Allen, L. F. (2015). Qualitative and quantitative validation of the FACIT-fatigue scale in iron deficiency anemia. Health and Quality of Life Outcomes, 13, 60. https://doi.org/10.1186/s12955-015-0257-x
Berentsen, S., & Barcellini, W. (2021). Autoimmune hemolytic anemias. New England Journal of Medicine, 385(1), 1407–1419. https://doi.org/10.1056/NEJMra2033982
Berentsen, S., Barcellini, W., D’Souza, S., & Jilma, B. (2022). Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? Immunotherapy, 14(15), 1191–1204. https://doi.org/10.2217/imt-2022-0085
Berentsen, S., Barcellini, W., D’Sa, S., Broome, C., Jilma, B., Michel, M.,...Tjonnfirord, G. E. (2020). Cold agglutinin disease revisited: A multi-national, observational study of 232 patients. Blood, 136(4), 480–488. https://doi.org/10.1182/blood.2020005674
Berentsen, S., D’Souza, S., Randan, U., Malecka, A., & Vos, J. (2022). Cold agglutinin disease: Improved understanding of pathogenesis helps define targets for therapy. Hemato, 3, 574-594. https://doi.org/10.3390/hemato3040040
Broome, C., Barcellini, W., Ueda, Y., Khan, U., Patel, R., Wardęcki, M.,...Roeth, A. (2023). Combined safety data for sutimlimab in cold agglutinin disease: A post hoc analysis of the phase 3 CARDINAL and CADENZA studies. Blood, 142(Supplement 1), 3833. https://doi.org/10.1182/blood-2023-188686
Broome, C., Cunningham, J., Mullins, M., Jiang, X., Bylsma, L., Fryzek, J., & Rosenthal, A. (2020). Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis. Research and Practice in Thrombosis and Haemostasis, 4(4), 628–635. https://doi.org/10.1002/rth2.12333
Bylsma, L., Gulbech Ording, A., Rosenthal, A., Öztürk, B., Fryzek, J., Morales Arias, J.,…Berentsen, S. (2019). Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. Blood Advances, 3(20), 2980–2985. https://doi.org/10.1182/bloodadvances.2019000476
Dhillon, S. (2022). Sutimlimab: First approval. Drugs, 82(7), 817–823. https://doi.org/10.1007/s40265-022-01711-5
Fattizzo, B., Röth, A., Broome, C. M., Khan, U., Wardęcki, M., Cordoba, M., & Barcellini, W. (2024). COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab. American Journal of Hematology, 99, 789–791. https://doi.org/10.1002/ajh.27234
Hill, Q. A., Röth, A., Jilma, B., Broome, C., Berentsen, S., Rizio, A.,...Cella, D. (2021). Fatigue score for patients with cold agglutinin disease: An analysis using the phase 3 CARDINAL and CADENZA studies. EHA Library. https://library.ehaweb.org/eha/2021/eha2021-virtualcongress/324900/quentin.a.hill.clinically.important.change.in.facit-fatigue.score.for.patients.html
Khellaf, M., Charles-Nelson, A., Fain, O., Terriou, L., Viallard, J. F., Cheze, S.,...Godeau, B. (2014). Safety and efficacy of rituximab in adult immune thrombocytopenia: Results from a prospective registry including 248 patients. Blood, 124(22), 3228–3236. https://doi.org/10.1182/blood-2014-06-582346
Kroger, A., Bahta, L., & Hunter, P. (2022). General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP): Altered Immunocompetence General Best Practice Guidelines for Immunization. CDC. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html.
Moore, D., & Arnall, J. (2023). Sutimlimab: A complement C1s inhibitor for the management of cold agglutinin disease-associated hemolysis. Annals of Pharmacotherapy, 57(8), 970-977. https://doi.org/10.1177/10600280221138802
Murthy, N., Wodi, A. P., Bernstein, H., & Ault, K. A. (2022). Recommended adult immunization schedule, United States. Annals of Internal Medicine, 175(3), 432–443. https://doi.org/10.7326/M22-0036
Piatek, C., Murakhovskaya, I., Karaouni, A., Miles, G., Heller, C., Lucia, J.,...Gertz, M. (2023). A U.S. retrospective observational study of rituximab use in cold agglutinin disease. Blood, 142(Supplement 1), 3835. https://doi.org/10.1182/blood-2023-172563
Röth, A., Barcellini, W., D’Sa, S., Miyakawa, Y., Broome, C. M., Michel, M.,…Berentsen, S. (2021). Sutimlimab in cold agglutinin disease. New England Journal of Medicine, 384(14), 1323–1334. https://doi.org/10.1056/NEJMoa2027760
Röth, A., Berensten, S., Barcellini, W., D’Sa, S., Jilma, B., Michel, M.,...Broome, C. (2022). Sutimlimab in patients with cold agglutinin disease: Results of the randomized placebo-controlled phase 3 CADENZA trial. Blood, 140(9), 980–991. https://doi.org/10.1182/blood.2021014955
Röth, A., Bommer, M., Hüttmann, A., Herich-Terhürne, D., Kuklik, N., Rekowski, J.,…Dührsen, U. (2018). Eculizumab in cold agglutinin disease (DECADE): An open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Advances, 2(19), 2543–2549. https://doi.org/10.1182/bloodadvances.2018024190
Röth, A., Ueda, Y., McCrae, K., Khan, U., Kralova, K., Wardęcki, M.,…Broome, C. (2023). Thromboembolic events in cold agglutinin disease: A post hoc analysis pre- and on-sutimlimab treatment in the phase 3 CARDINAL and CADENZA studies. Hämostaseologie, 44, 17–18. https://doi.org/10.1055/s-0044-1779082
Sanofi. (2023). Enjaymo (sutimlimab) package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761164s003lbl.pdf
Sokol, R. J., Hewitt, S., & Stamps, B. K. (1981). Autoimmune hemolysis: An 18-year study of 865 cases referred to a regional transfusion centre. British Medical Journal (Clinical Research Edition), 282, 2023–2027. https://doi.org/10.1136/bmj.282.6281.2023
